The role of gene polymorphisms in individually changing of the lipid profile among patients with coronary artery disease under the influence of the statin therapy
DOI:
https://doi.org/10.34287/MMT.3(42).2019.13Abstract
Ischemic heart disease is one of the urgent problems in modern cardiology, which is associated with a wide spread of disability and mortality mainly among young and employable aged people. The therapeutic drugs effect is individual and depends on the genetic characteristics of the patient. The aim of the study. Analysis of modern literature sources related to the role of gene polymorphisms in individual lipid profile changing among patients with coronary artery disease under the influence of the statin therapy.
Literature review. Pharmacotherapy while ischemic heart disease (IHD) provides for mandatory preventive services aimed at the eliminating of modifying risk factors of coronary heart disease. One of the most important indicators of successful treatment of patients with IHD is a lipid metabolism state, that is why treatment can’t be imagined without the inclusion of statins in therapeutic schemes of dyslipidemia correction. The current understanding of the statins effectiveness is based on the knowledge of molecular mechanisms underlying the pharmacokinetics and pharmacodynamics processes. In clinical practice, while taking statins with absolute compliance of patients and elimination of all modifying factors, lipid metabolism parameters are not always normalized, this indicates characteristics of the patients’ genetic. Of particular importance is the effect of genotype on pharmacotherapy using protein transporters, carriers of endogenous compounds or xenobiotics through biological membranes assisted by passive or active mechanisms. Single-nucleotide polymorphisms (SNPs) of transport proteins can change the absorption and excretion degree of drugs and their metabolites. Polypeptides of organic anions membrane transporters that regulate cell uptake of certain endogenous substances and drugs are encoded by SLCO genes. One of the main absorption protein transporters is OATP1B1. It is established that the effects of some SLCO1B1 SNPs on transport function are substrate dependent, and the most studied among them are с.521Т>С and с.388А>G. The c.521Т>C and с.388А>G polymorohisms c.521T>C". Но c.521T>C are in an intermittent contact with each other, and despite this they exist in a variety of SLCO1B1-haplotypes. The c.388А-521Т haplotypes known as *1A ones, c.388G-521Т as *1B, c. 388А-521С as *5 and c.388G-521С as *15. One of the first studies showed that *5 and *15 haplotypes were associated with a decrease in the absorption of statins. In further studies of c.521C allele it was found a related increase of the statins concentration in human plasma, which leads to the progression of undesirable reactions such as myalgia, myopathy, and even rhabdomyolysis, asymptomatic increase transaminase activity and abdominal pain. The study of SLCO1B1 pharmacogenetics found that dysfunction of the protein-transporter leads to reduced absorption by the liver cells, the increasing of plasma concentrations and the change in the body's response to stationery.
Conclusion. Analysis of the literature indicates that the therapeutic effect of statins in combination with genetic polymorphisms may have an individual effect on the pharmacokinetics of these drugs. To study the influence of SLCO1B1 c.521Т>С gene polymorphism there are needed the further researches in populations with IHD. A more detailed study of this polymorphism from the perspective of personalized therapy will allow developing individual approaches to the appointment of statins.
References
Vishnevsky AG, Andreev EM, Timonin SA. Mortality from circulatory system diseases and life expectancy in Russia. Demograficheskoye obozreniye. 2016; 3 (1): 6–34.
European statistical data base «Zdorovya dlya vsikh». http://medstat.gov.ua/ukr/normdoc.html.
Melnyk PS, Slabky GO, Dzyuba OM et al. (editorial board). Report annual on the state of health of the population, the sanitary-epidemic situation and the results of the health care system of Ukraine. 2016 / Ministry of Health of Ukraine, SI «UISS Ministry of Health of Ukraine». Kyiv, 2017.
Ozdemir V, Kalow W, Tang BK et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000; 10 (5): 373–388.
Turner RM, Pirmohamed M. Cardiovascular pharmacogenomics: expectations and practical benefits. Clinical Pharmacology and Therapeutics. 2014; 95 (3): 281–293. DOI: 10.1038/clpt.2013.234.
Blake CM, Kharasch ED, Schwab M, Nagele P. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clinical Pharmacology and Therapeutics. 2013. 94 (3): 394–399. DOI: 10.1038/clpt.2013.96.
Brugts JJ, Simoons ML. Genetic influences of angiotensin-converting enzyme inhibitor response: an opportunity for personalizing therapy? Expert Rev. Cardiovasc. Ther. 2012. 10 (8): 1001–1009.
Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy a genomewide study. N Engl J Med. 2008; 359 (8): 789–799. DOI: 10.1056/NEJMoa0801936.
Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129: S1–S45.
Canestaro WJ., Brooks DG., Chaplin D et al. Statin Pharmocogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing. Journal of Personalized Medicine. 2012; 2 (4): 158–174. DOI: 10.3390/jpm2040158.
FDA Expands Advice on Statin Risks// http://www/fda.gov/downloads/for Consumers/ Consumer Updates/UCM293705.
Giacomini KM, Huang SM, Tweedie DJ et al. Membrane transporters in drug development. Nat. Rev Drug Discov. 2010; 9 (3): 215–236. DOI: 10.1038/nrd3028.
Huang Y, Sadee W. Membrane transporters and channels in chemoresistance and sensitivity of tumor cells // Cancer Letters. 2006; 239 (2): 168–182. DOI: 10.1016/j.canlet.2005.07.032.
Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/ functional properties. Pflugers. Arch. 2004; 447 (5): 653–665. DOI: 10.1007/s00424-003-1168-y.
König J, Seithel A, Gradhand U et al. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 2006; 372 (6): 432–443. DOI: 10.1007/s00210-006-0040-y.
Briz O, Romero MR, Martinez-Becerra P et al. OATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes? J Biol Chem. 2006; 281 (41): 30326–30335.
Tamai I, Nezu J, Uchino H et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000; 273 (1): 251–260. DOI: 10.1006/bbrc.2000.2922.
SNPs database of National Center for Biotechnology Information (NCBI). URL: http://www.ncbi.nlm.nih.gov/projects/SNP/.
Iwai M, Suzuki H, Ieiri I et al. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics. 2004; 14 (11): 749–757.
Kameyama Y, Yamashita K, Kobayashi K et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics. 2005; 15 (7): 513–522.
Pasanen MK, Neuvonen M, Neuvonen PJ et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006; 16 (12): 873–879. DOI: 10.1097/01.fpc.0000230416.82349.90.
Pasanen MK, Fredrikson H, Neuvonen PJ et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007; 82 (6): 726–733. DOI: 10.1038/sj.clpt.6100220.
Deng JW, Song IS, Shin HJ et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008; 18 (5): 424–433. DOI: 10.1097/FPC.0b013e3282fb02a3.
Ieiri I, Suwannakul S, Maeda K et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2007; 82 (5): 541–547. DOI: 10.1038/sj.clpt.6100190.
Pasanen MK, Neuvonen M, Neuvonen PJ et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006; 16 (12): 873–879. DOI: 10.1097/01.fpc.0000230416.82349.90.
He YJ, Zhang W, Chen Y et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009; 405 (1–2): 49–52. DOI: 10.1016/j.cca.2009.04.003.
Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006; 80 (4): 356–366. DOI: 10.1016/j.clpt.2006.06.010.
Morimoto K, Oishi T, Ueda S et al. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet. 2004; 19 (6): 453–455.
Link E, Parish S, Armitage J et al. SLCO1B1 Variants and statin-induced myopathy – a genomewide study. N Engl J Med. 2008; 359 (8): 789–799. DOI: 10.1056/NEJMoa0801936.
Voora D, Shah SH, Spasojevic I et al. The SLCO1B1*5 genetic variant is associated with statininduced side effects. J Am Coll Cardiol. 2009; 54 (17): 1609–1616. DOI: 10.1016/j.jacc.2009.04.053.
Brunham LR, Lansberg PJ, Zhang L. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2012; 12 (3): 233–237. DOI: 10.1038/tpj.2010.92.
